Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to determine the safety and efficacy of ibuprofen, compared with indomethacin, in the treatment for the closure of the patent ductus arteriosus in premature babies born under 29 weeks gestation


Clinical Trial Description

According to Very Low Birth Weight (VLBW) High Risk Registration database in KKWCH, a hemodynamically significant patent ductus arteriosus (PDA) is a common problem in very premature infants born at a gestational age of 29 weeks and under, with more than 50% of them needing indomethacin treatment for closure of the PDA.

Prostaglandins play a major role in keeping the ductus patent . Indomethacin, because of its anti-prostaglandin effect via inhibition of the prostaglandin forming cyclo-oxygenase enzymes, has been used to medically close the PDA since the 1970s. Concerns with this drug relate to its effect on cerebral, renal and gastrointestinal blood flow. Necrotising enterocolitis (NEC), gastrointestinal perforation, gastrointestinal bleeding, transient or permanent renal impairment and reduced cerebral blood flow have been associated with indomethacin.

Ibuprofen treatment for PDA have been reported in the 1990s. It is as effective as indomethacin in closing the PDA. It is potentially better than indomethacin because regional blood flows were not affected. The few trials that have been done comparing intravenous ibuprofen and indomethacin involved mainly heavier very low birth weight (VLBW) infants. In a New England Journal of Medicine editorial on this subject, Clyman pointed out the need for trials involving the very immature infants to look at efficacy and safety.

The main obstacle for ibuprofen use in premature infants is the absence of a commercially available intravenous preparation. In our proposed trial a new i.v. ibuprofen preparation manufactured by Cumberland Pharmaceuticals (Nashville, Tennessee) will be used.

A Cochrane systematic review on ibuprofen for the treatment of PDA in premature infants concluded that it performed with the same effectiveness when compared to indomethacin. There was a significant decrease in the incidence of oliguria in the ibuprofen arm, with a higher risk of chronic lung disease at 28 days of life (borderline statistical significance), but not at 36 weeks.There is no biologically plausible explanation for the latter effect and this could be attributed to chance in view of this, plus the weak statistical proof. The other problem with this review was that it included trials where enteral ibuprofen was used, and this route is clearly impractical in the very premature infants which we plan to study because of the unpredictable absorption from the immature gut and their general intolerance to feeding at such an early age. The concern regarding pulmonary hypertension with the prophylactic use of ibuprofen also should not apply to our planned study where the time of administration of the drugs will be around 24 hours of age.

The potential benefits stemming from ibuprofen's biological advantage over indomethacin will be reduction in the rates of oliguria, gastrointestinal bleeding, NEC and gastrointestinal perforation. NEC and gastrointestinal perforation are conditions with serious morbidities and usually result in prolonged hospital stay and poorer neurodevelopmental outcome for the affected infants. A better drug could lead to cost savings.

Neurosensory impairment is an important outcome to monitor because indomethacin reduces cerebral blood flow. This point was also emphasized in the Cochrane systematic review mentioned above. However this will be the subject of another proposal in view of the significant additional budget needed.

The objective of the trial is to compare, the the safety and efficacy of intravenous ibuprofen treatment for the closure of the patent ductus arteriosus diagnosed via 2D echocardiography in very premature babies born under 29 weeks of gestation, with traditional therapy indomethacin.

The primary outcome measure will be the incidence of oliguria and gastric bleeding within one week after the 1st dose of treatment ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00470743
Study type Interventional
Source KK Women's and Children's Hospital
Contact
Status Withdrawn
Phase Phase 4
Start date May 2007
Completion date June 2009

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03604796 - Alternative Paracetamol Treatments for the Neonate With a hsPDA Phase 2/Phase 3
Completed NCT00000494 - Management of Patent Ductus in Premature Infants Phase 3
Completed NCT01251939 - Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious N/A
Completed NCT01031316 - Patent Ductus Arteriosus (PDA) Screening Trial N/A
Completed NCT00828334 - NIT-OCCLUD PDA Phase II Sentinel Trial N/A
Completed NCT00009646 - Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP) Phase 3
Completed NCT00725647 - Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies N/A
Terminated NCT00239512 - New Management Strategy of PDA for VLBW Preterm Infants N/A
Recruiting NCT04508036 - Ductus Arteriosus Closure and D-Dimer and Fibrinogen Levels
Completed NCT01243996 - High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant Phase 2/Phase 3
Completed NCT00005190 - Reproduction and Survival After Cardiac Defect Repair N/A
Not yet recruiting NCT04205877 - The U.S. PDA Registry
Recruiting NCT05547165 - Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants N/A
Completed NCT02422966 - Paracetamol in Patent Ductus Arteriosus Phase 2
Completed NCT02803671 - Analysis of the Impact of Patent Ductus Arteriosus on Brain Function in Preterm Neonates: Multimodal Approach Integrating EEG-NIRS, Ultrasound and Clinical Data N/A
Completed NCT00799123 - Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) Infants N/A
Completed NCT00528736 - Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks N/A
Completed NCT02002741 - Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants Phase 2/Phase 3